1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Takeda calls time on ramelteon in Europe

 
• By Ian Haydock

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

A submission for 4mg and 8mg tablets of the melatonin MT1 and MT2 receptor agonist had been made under the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Therapeutic Category